{"pmid":32091395,"pmcid":"PMC7060038","title":"Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19.","text":["Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19.","Traveller screening is being used to limit further spread of COVID-19 following its recent emergence, and symptom screening has become a ubiquitous tool in the global response. Previously, we developed a mathematical model to understand factors governing the effectiveness of traveller screening to prevent spread of emerging pathogens (Gostic et al., 2015). Here, we estimate the impact of different screening programs given current knowledge of key COVID-19 life history and epidemiological parameters. Even under best-case assumptions, we estimate that screening will miss more than half of infected people. Breaking down the factors leading to screening successes and failures, we find that most cases missed by screening are fundamentally undetectable, because they have not yet developed symptoms and are unaware they were exposed. Our work underscores the need for measures to limit transmission by individuals who become ill after being missed by a screening program. These findings can support evidence-based policy to combat the spread of COVID-19, and prospective planning to mitigate future emerging pathogens.","Elife","Gostic, Katelyn","Gomez, Ana Cr","Mummah, Riley O","Kucharski, Adam J","Lloyd-Smith, James O","32091395"],"abstract":["Traveller screening is being used to limit further spread of COVID-19 following its recent emergence, and symptom screening has become a ubiquitous tool in the global response. Previously, we developed a mathematical model to understand factors governing the effectiveness of traveller screening to prevent spread of emerging pathogens (Gostic et al., 2015). Here, we estimate the impact of different screening programs given current knowledge of key COVID-19 life history and epidemiological parameters. Even under best-case assumptions, we estimate that screening will miss more than half of infected people. Breaking down the factors leading to screening successes and failures, we find that most cases missed by screening are fundamentally undetectable, because they have not yet developed symptoms and are unaware they were exposed. Our work underscores the need for measures to limit transmission by individuals who become ill after being missed by a screening program. These findings can support evidence-based policy to combat the spread of COVID-19, and prospective planning to mitigate future emerging pathogens."],"journal":"Elife","authors":["Gostic, Katelyn","Gomez, Ana Cr","Mummah, Riley O","Kucharski, Adam J","Lloyd-Smith, James O"],"date":"2020-02-25T11:00:00Z","year":2020,"_id":"32091395","week":"20209|Feb 24 - Mar 01","doi":"10.7554/eLife.55570","keywords":["COVID-19","SARS-CoV-2","emerging infectious disease","epidemic containment","epidemic control","epidemiology","global health","human","travel screening","virus"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647426084865,"score":6.7365713,"similar":[{"pmid":32165854,"pmcid":"PMC7061485","title":"Coronavirus disease-2019: is fever an adequate screening for the returning travelers?","text":["Coronavirus disease-2019: is fever an adequate screening for the returning travelers?","On Thursday, 30 January 2020, World Health Organization declared Coronavirus disease-2019 (COVID-2019) a Public Health Emergency of International Concern. Since its identification in late December 2019 in Wuhan, Hubei Province, People's Republic of China, the number of cases imported into other countries is increasing, and the epidemiological map is changing rapidly. On the other hand, body temperature screening (fever) is the major test performed at points of entry, i.e., airports, in the returning travelers in most of the countries with limited resources. However, the recent report on asymptomatic contact transmission of COVID-19 and travelers who passed the symptoms-based screening and tested positive for COVID-19 using reverse transcription polymerase chain reaction (RT-PCR) challenges this approach as body temperature screening may miss travelers incubating the disease or travelers concealing fever during travel. On this note, travel restrictions to and from high risk areas and/or 14 days quarantine of travelers coming from high risk areas are recommended to prevent possible importation of COVID-19. Currently, RT-PCR is a reliable test in detecting both symptomatic and asymptomatic COVID-19.","Trop Med Health","Bwire, George M","Paulo, Linda S","32165854"],"abstract":["On Thursday, 30 January 2020, World Health Organization declared Coronavirus disease-2019 (COVID-2019) a Public Health Emergency of International Concern. Since its identification in late December 2019 in Wuhan, Hubei Province, People's Republic of China, the number of cases imported into other countries is increasing, and the epidemiological map is changing rapidly. On the other hand, body temperature screening (fever) is the major test performed at points of entry, i.e., airports, in the returning travelers in most of the countries with limited resources. However, the recent report on asymptomatic contact transmission of COVID-19 and travelers who passed the symptoms-based screening and tested positive for COVID-19 using reverse transcription polymerase chain reaction (RT-PCR) challenges this approach as body temperature screening may miss travelers incubating the disease or travelers concealing fever during travel. On this note, travel restrictions to and from high risk areas and/or 14 days quarantine of travelers coming from high risk areas are recommended to prevent possible importation of COVID-19. Currently, RT-PCR is a reliable test in detecting both symptomatic and asymptomatic COVID-19."],"journal":"Trop Med Health","authors":["Bwire, George M","Paulo, Linda S"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32165854","week":"202011|Mar 09 - Mar 15","doi":"10.1186/s41182-020-00201-2","keywords":["COVID-19","Fever","Returning travelers","Temperature screening"],"source":"PubMed","locations":["Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1661359647940935681,"score":233.36899},{"pmid":32093043,"title":"Risk Assessment of Novel Coronavirus COVID-19 Outbreaks Outside China.","text":["Risk Assessment of Novel Coronavirus COVID-19 Outbreaks Outside China.","We developed a computational tool to assess the risks of novel coronavirus outbreaks outside of China. We estimate the dependence of the risk of a major outbreak in a country from imported cases on key parameters such as: (i) the evolution of the cumulative number of cases in mainland China outside the closed areas; (ii) the connectivity of the destination country with China, including baseline travel frequencies, the effect of travel restrictions, and the efficacy of entry screening at destination; and (iii) the efficacy of control measures in the destination country (expressed by the local reproduction number R loc ). We found that in countries with low connectivity to China but with relatively high R loc , the most beneficial control measure to reduce the risk of outbreaks is a further reduction in their importation number either by entry screening or travel restrictions. Countries with high connectivity but low R loc benefit the most from policies that further reduce R loc . Countries in the middle should consider a combination of such policies. Risk assessments were illustrated for selected groups of countries from America, Asia, and Europe. We investigated how their risks depend on those parameters, and how the risk is increasing in time as the number of cases in China is growing.","J Clin Med","Boldog, Peter","Tekeli, Tamas","Vizi, Zsolt","Denes, Attila","Bartha, Ferenc A","Rost, Gergely","32093043"],"abstract":["We developed a computational tool to assess the risks of novel coronavirus outbreaks outside of China. We estimate the dependence of the risk of a major outbreak in a country from imported cases on key parameters such as: (i) the evolution of the cumulative number of cases in mainland China outside the closed areas; (ii) the connectivity of the destination country with China, including baseline travel frequencies, the effect of travel restrictions, and the efficacy of entry screening at destination; and (iii) the efficacy of control measures in the destination country (expressed by the local reproduction number R loc ). We found that in countries with low connectivity to China but with relatively high R loc , the most beneficial control measure to reduce the risk of outbreaks is a further reduction in their importation number either by entry screening or travel restrictions. Countries with high connectivity but low R loc benefit the most from policies that further reduce R loc . Countries in the middle should consider a combination of such policies. Risk assessments were illustrated for selected groups of countries from America, Asia, and Europe. We investigated how their risks depend on those parameters, and how the risk is increasing in time as the number of cases in China is growing."],"journal":"J Clin Med","authors":["Boldog, Peter","Tekeli, Tamas","Vizi, Zsolt","Denes, Attila","Bartha, Ferenc A","Rost, Gergely"],"date":"2020-02-26T11:00:00Z","year":2020,"_id":"32093043","week":"20209|Feb 24 - Mar 01","doi":"10.3390/jcm9020571","keywords":["COVID-19","branching process","compartmental model","interventions","novel coronavirus","outbreak","risk assessment","transmission","travel"],"source":"PubMed","locations":["America","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Epidemic Forecasting"],"weight":1,"_version_":1661359647441813504,"score":202.45778},{"pmid":32133832,"title":"[Potential false-positive rate among the 'asymptomatic infected individuals' in close contacts of COVID-19 patients].","text":["[Potential false-positive rate among the 'asymptomatic infected individuals' in close contacts of COVID-19 patients].","Objective: As the prevention and control of COVID-19continues to advance, the active nucleic acid test screening in the close contacts of the patients has been carrying out in many parts of China. However, the false-positive rate of positive results in the screening has not been reported up to now. But to clearify the false-positive rate during screening is important in COVID-19 control and prevention. Methods: Point values and reasonable ranges of the indicators which impact the false-positive rate of positive results were estimated based on the information available to us at present. The false-positive rate of positive results in the active screening was deduced, and univariate and multivariate-probabilistic sensitivity analyses were performed to understand the robustness of the findings. Results: When the infection rate of the close contacts and the sensitivity and specificity of reported results were taken as the point estimates, the positive predictive value of the active screening was only 19.67%, in contrast, the false-positive rate of positive results was 80.33%. The multivariate-probabilistic sensitivity analysis results supported the base-case findings, with a 75% probability for the false-positive rate of positive results over 47%. Conclusions: In the close contacts of COVID-19 patients, nearly half or even more of the 'asymptomatic infected individuals' reported in the active nucleic acid test screening might be false positives.","Zhonghua Liu Xing Bing Xue Za Zhi","Zhuang, G H","Shen, M W","Zeng, L X","Mi, B B","Chen, F Y","Liu, W J","Pei, L L","Qi, X","Li, C","32133832"],"abstract":["Objective: As the prevention and control of COVID-19continues to advance, the active nucleic acid test screening in the close contacts of the patients has been carrying out in many parts of China. However, the false-positive rate of positive results in the screening has not been reported up to now. But to clearify the false-positive rate during screening is important in COVID-19 control and prevention. Methods: Point values and reasonable ranges of the indicators which impact the false-positive rate of positive results were estimated based on the information available to us at present. The false-positive rate of positive results in the active screening was deduced, and univariate and multivariate-probabilistic sensitivity analyses were performed to understand the robustness of the findings. Results: When the infection rate of the close contacts and the sensitivity and specificity of reported results were taken as the point estimates, the positive predictive value of the active screening was only 19.67%, in contrast, the false-positive rate of positive results was 80.33%. The multivariate-probabilistic sensitivity analysis results supported the base-case findings, with a 75% probability for the false-positive rate of positive results over 47%. Conclusions: In the close contacts of COVID-19 patients, nearly half or even more of the 'asymptomatic infected individuals' reported in the active nucleic acid test screening might be false positives."],"journal":"Zhonghua Liu Xing Bing Xue Za Zhi","authors":["Zhuang, G H","Shen, M W","Zeng, L X","Mi, B B","Chen, F Y","Liu, W J","Pei, L L","Qi, X","Li, C"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32133832","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn112338-20200221-00144","keywords":["COVID-19","Close contacts","False-positive","Nucleic acid test","Screening"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1661359647725977600,"score":187.8586},{"pmid":32046816,"pmcid":"PMC7014668","title":"Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV).","text":["Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV).","We evaluated effectiveness of thermal passenger screening for 2019-nCoV infection at airport exit and entry to inform public health decision-making. In our baseline scenario, we estimated that 46% (95% confidence interval: 36 to 58) of infected travellers would not be detected, depending on incubation period, sensitivity of exit and entry screening, and proportion of asymptomatic cases. Airport screening is unlikely to detect a sufficient proportion of 2019-nCoV infected travellers to avoid entry of infected travellers.","Euro Surveill","Quilty, Billy J","Clifford, Sam","Flasche, Stefan","Eggo, Rosalind M","32046816"],"abstract":["We evaluated effectiveness of thermal passenger screening for 2019-nCoV infection at airport exit and entry to inform public health decision-making. In our baseline scenario, we estimated that 46% (95% confidence interval: 36 to 58) of infected travellers would not be detected, depending on incubation period, sensitivity of exit and entry screening, and proportion of asymptomatic cases. Airport screening is unlikely to detect a sufficient proportion of 2019-nCoV infected travellers to avoid entry of infected travellers."],"journal":"Euro Surveill","authors":["Quilty, Billy J","Clifford, Sam","Flasche, Stefan","Eggo, Rosalind M"],"date":"2020-02-13T11:00:00Z","year":2020,"_id":"32046816","week":"20207|Feb 10 - Feb 16","doi":"10.2807/1560-7917.ES.2020.25.5.2000080","keywords":["*2019-nCoV","*airport screening","*effectiveness","*emerging infections","*interventions","*surveillance","*thermal scanning"],"link_erratum_in":"32070469","source":"PubMed","topics":["General Info"],"weight":1,"_version_":1661359647237341185,"score":176.72559},{"pmid":32162456,"title":"Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.","text":["Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.","The recently emerged 2019 Novel Coronavirus (SARS-CoV-2) and associated COVID-19 disease cause serious or even fatal respiratory tract infection and yet no approved therapeutics or effective treatment is currently available to effectively combat the outbreak. This urgent situation is pressing the world to respond with the development of novel vaccine or a small molecule therapeutics for SARS-CoV-2. Along these efforts, the structure of SARS-CoV-2 main protease (Mpro) has been rapidly resolved and made publicly available to facilitate global efforts to develop novel drug candidates. Recently, our group has developed a novel deep learning platform - Deep Docking (DD) which provides fast prediction of docking scores of Glide (or any other docking program) and, hence, enables structure-based virtual screening of billions of purchasable molecules in a short time. In the current study we applied DD to all 1.3 billion compounds from ZINC15 library to identify top 1,000 potential ligands for SARS-CoV-2 Mpro protein. The compounds are made publicly available for further characterization and development by scientific community.","Mol Inform","Ton, Anh-Tien","Gentile, Francesco","Hsing, Michael","Ban, Fuqiang","Cherkasov, Artem","32162456"],"abstract":["The recently emerged 2019 Novel Coronavirus (SARS-CoV-2) and associated COVID-19 disease cause serious or even fatal respiratory tract infection and yet no approved therapeutics or effective treatment is currently available to effectively combat the outbreak. This urgent situation is pressing the world to respond with the development of novel vaccine or a small molecule therapeutics for SARS-CoV-2. Along these efforts, the structure of SARS-CoV-2 main protease (Mpro) has been rapidly resolved and made publicly available to facilitate global efforts to develop novel drug candidates. Recently, our group has developed a novel deep learning platform - Deep Docking (DD) which provides fast prediction of docking scores of Glide (or any other docking program) and, hence, enables structure-based virtual screening of billions of purchasable molecules in a short time. In the current study we applied DD to all 1.3 billion compounds from ZINC15 library to identify top 1,000 potential ligands for SARS-CoV-2 Mpro protein. The compounds are made publicly available for further characterization and development by scientific community."],"journal":"Mol Inform","authors":["Ton, Anh-Tien","Gentile, Francesco","Hsing, Michael","Ban, Fuqiang","Cherkasov, Artem"],"date":"2020-03-13T11:00:00Z","year":2020,"_id":"32162456","week":"202011|Mar 09 - Mar 15","doi":"10.1002/minf.202000028","keywords":["COVID-19","Deep learning","SARS-CoV-2","protease inhibitors","virtual screening"],"source":"PubMed","locations":["ZINC15"],"topics":["Treatment"],"weight":1,"_version_":1661359647894798338,"score":167.87221}]}